JP2023502876A - がんの治療のためのｈｅｒ２／４－１ｂｂ二重特異性融合タンパク質 - Google Patents

がんの治療のためのｈｅｒ２／４－１ｂｂ二重特異性融合タンパク質 Download PDF

Info

Publication number
JP2023502876A
JP2023502876A JP2022525630A JP2022525630A JP2023502876A JP 2023502876 A JP2023502876 A JP 2023502876A JP 2022525630 A JP2022525630 A JP 2022525630A JP 2022525630 A JP2022525630 A JP 2022525630A JP 2023502876 A JP2023502876 A JP 2023502876A
Authority
JP
Japan
Prior art keywords
fusion protein
once
dose
use according
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525630A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502876A5 (https=
Inventor
シャネ オルウィル
ルイス マティス
イングマル ブルンス
マヌエラ デュアー
ルシュディア ザリーン ユスフ
マルクス ツェトル
アンドレア アラースドルファー
アイジー モラレス カストレザナ
コリナ シュロッサー
Original Assignee
ピエリス ファーマシューティカルズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピエリス ファーマシューティカルズ ゲーエムベーハー filed Critical ピエリス ファーマシューティカルズ ゲーエムベーハー
Publication of JP2023502876A publication Critical patent/JP2023502876A/ja
Publication of JP2023502876A5 publication Critical patent/JP2023502876A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022525630A 2019-11-04 2020-11-04 がんの治療のためのｈｅｒ２／４－１ｂｂ二重特異性融合タンパク質 Pending JP2023502876A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962930512P 2019-11-04 2019-11-04
US62/930,512 2019-11-04
US202063080361P 2020-09-18 2020-09-18
US63/080,361 2020-09-18
PCT/EP2020/080892 WO2021089588A1 (en) 2019-11-04 2020-11-04 Her2/4-1bb bispecific fusion proteins for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2023502876A true JP2023502876A (ja) 2023-01-26
JP2023502876A5 JP2023502876A5 (https=) 2023-11-13

Family

ID=73598820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525630A Pending JP2023502876A (ja) 2019-11-04 2020-11-04 がんの治療のためのｈｅｒ２／４－１ｂｂ二重特異性融合タンパク質

Country Status (8)

Country Link
US (1) US20240166763A1 (https=)
EP (1) EP4054718A1 (https=)
JP (1) JP2023502876A (https=)
KR (1) KR20220097952A (https=)
CN (1) CN116348478A (https=)
AU (1) AU2020379176A1 (https=)
CA (1) CA3154881A1 (https=)
WO (1) WO2021089588A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023541482A (ja) 2020-09-18 2023-10-02 ピエリス ファーマシューティカルズ ゲーエムベーハー バイオマーカー法および使用法
EP4644417A4 (en) * 2022-12-30 2026-02-11 Abclon Inc AFFICORPS SPECIFICALLY BINDING TO CD137 AND ITS USE
CN116103244A (zh) * 2023-04-12 2023-05-12 河北科技大学 一种单信号激活型til细胞的制备方法及应用
KR20250148463A (ko) * 2024-04-03 2025-10-14 주식회사유한양행 담도암의 치료를 위한 항-her2/항-4-1bb 이중 특이 항체

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104406A2 (en) * 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
JP2018515085A (ja) * 2015-05-04 2018-06-14 ピエリス ファーマシューティカルズ ゲーエムベーハー 抗がん融合ポリペプチド

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
WO2003029471A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
CN114573680A (zh) 2015-05-04 2022-06-03 皮里斯制药有限公司 Cd137特异性的蛋白

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104406A2 (en) * 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
JP2018515085A (ja) * 2015-05-04 2018-06-14 ピエリス ファーマシューティカルズ ゲーエムベーハー 抗がん融合ポリペプチド

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CANCER RES, vol. 77 (13_Supplement), JPN6024042617, 2017, pages 3673, ISSN: 0005589777 *
CLIN CANCER RES, vol. 25(19), JPN6024042613, 2019, pages 5878 - 89, ISSN: 0005589775 *
CLIN CANCER RES, vol. 25, no. 10, JPN6024042618, 2019, pages 3054 - 3062, ISSN: 0005589779 *
J GASTROINTEST ONCOL, vol. 4(4), JPN6024042615, 2013, pages 19 - 22, ISSN: 0005589776 *
J TRANS MED (2018), vol. 16:86, JPN6024042616, pages 1 - 11, ISSN: 0005589778 *
THE JOURNAL OF TOXICOLOGICAL SCIENCES, vol. 42, no. 6, JPN6024042612, 2017, pages 689 - 705, ISSN: 0005589774 *

Also Published As

Publication number Publication date
US20240166763A1 (en) 2024-05-23
KR20220097952A (ko) 2022-07-08
CN116348478A (zh) 2023-06-27
AU2020379176A1 (en) 2022-06-09
CA3154881A1 (en) 2021-05-14
EP4054718A1 (en) 2022-09-14
WO2021089588A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
JP7775347B2 (ja) 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
KR102638104B1 (ko) 이특이적 her2 및 cd3 결합 분자
JP7459058B2 (ja) Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法
KR20190080992A (ko) 삼중특이성 결합 단백질 및 사용 방법
JP2023502876A (ja) がんの治療のためのｈｅｒ２／４－１ｂｂ二重特異性融合タンパク質
JP7754506B2 (ja) ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
US20230366884A1 (en) Biomarker methods and uses
JP2022518399A (ja) Ｐｄ－１軸結合アンタゴニスト及びｒｎａワクチンを用いてがんを処置する方法
JP2024511620A (ja) がんの治療のためのｈｅｒ２／４－１ｂｂ二重特異性融合タンパク質
EP2985292A1 (en) Epidermal growth factor receptor antibody
CN107614524B (zh) 治疗
CN116333125A (zh) 结合死亡受体4和死亡受体5的抗体
HK40091842A (zh) 用於癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231102

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241022

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250508